According to filings with the U.S. Securities and Exchange Commission, Alpha Cognition is raising $2,149,152.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Mcfadden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alpha Cognition
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimers Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimers type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

To learn more about Alpha Cognition, visit http://www.alphacognition.com/

Contact:
Michael Mcfadden, Chief Executive Officer
858-344-4375
https://www.linkedin.com/in/mrpeapod/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.